Content area
Full text
Each abstract has been indexed according to first author. Abstracts appear as they were submitted and have not undergone editing or the Oncology Nursing Forum's review process. Only abstracts that will be presented appear here. For Congress scheduling information, visit congress.ons.org or check the Congress guide.
Data published in abstracts presented at the ONS 44th Annual Congress are embargoed until the conclusion of the presentation. Coverage and/or distribution of an abstract, poster, or any of its supplemental material to or by the news media, any commercial entity, or individuals, including the authors of said abstract, is strictly prohibited until the embargo is lifted. Promotion of general topics and speakers is encouraged within these guidelines.
ADVANCED PRACTICE
DEVELOPMENT OF AN ADVANCED PRACTICE PROVIDER ANTINEOPLASTIC THERAPY ORDERING PROTOCOL
Archana Ajmera, MSN, ANP-BC, AOCNP®, University of California San Diego, La Jolla, CA; Susan Wilson, PharmD, University of California San Diego, La Jolla, CA; Rana McKay, MD, University of California San Diego, La Jolla, CA
At the University of California San Diego Moores Cancer Center, one of 70 NCI-designated Comprehensive Cancer Centers, oncology Advanced Practice Providers (APPs) work in partnership with medical oncologists to provide specialized care to patients and their families. Historically, our Antineoplastic Therapy Ordering Protocol has been limited in scope with restrictions on APP authorization of intravenous antineoplastic therapy. With the support of a multidisciplinary provider team, we developed a program including a standardized protocol, competency assessment and ongoing evaluation of APP authorization of intravenous antineoplastic therapy to ensure safe and efficient care delivery while expanding the scope of practice of APPs at Moores Cancer Center. The objective was to establish an APP Antineoplastic Therapy Ordering Protocol, which grants APPs the privilege to sign and authorize continuation orders for established intravenous antineoplastic therapies. The program outlines that APPs granted privileges can demonstrate knowledge of the specific antineoplastic treatments, perform pre-treatment evaluation for each patient for whom they are signing orders, and communicate with the medical oncologist for any dose modifications made to the treatment plan. To ensure safety, the protocol's foundation includes a competency assessment and annual re-credentialing through the Medical Staff Credentialing Office. Evaluation for competency includes a requirement that APPs have three years of oncology experience and/ or Chemotherapy Biotherapy certification through the Oncology...